Publicacións (91) Publicacións de José Luis Díaz Díaz

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 11, pp. 811-823

  3. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  4. Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular

    Clínica e investigación en arteriosclerosis, Vol. 36, Núm. 3, pp. 133-194

  5. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet, Vol. 403, Núm. 10421, pp. 55-66

  6. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis, Vol. 393

  7. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

  8. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention

    Lipids in Health and Disease , Vol. 23, Núm. 1

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Control de la hipercolesterolemia en España: una misma situación con diferentes realidades autonómicas

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 5, pp. 219-225

  3. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet

  4. Impact of conducting a genetic study on the management of familial hypercholesterolemia; A retrospective cohort study of 4854 patients from the SEA Dyslipidemia Registry

    Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 717-731

  5. Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain

    Atherosclerosis, Vol. 375, pp. 38-44

  6. PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

  7. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

  8. Prevalencia de dislipemia aterogénica, factores relacionados y grado de control lipídico en la población general de Galicia: Estudio GALIPEMIAS

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 4, pp. 178-184

  9. Recomendaciones nutricionales en la prevención y tratamiento de la dislipemia aterogénica: Grupo de Trabajo Dislipemia Aterogénica, Sociedad Española de Arteriosclerosis

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 3, pp. 155-163

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study

    Medicina Clinica, Vol. 158, Núm. 11, pp. 531-539

  3. Dyslipidemia observatory: Treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 253-260